glucagon receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-22. Numbers and descriptions here follow the published literature rather than marketing material.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Açaí oil is suitable for cooking or as a salad dressing, but is mainly used in cosmetics as shampoos, soaps or skin moisturizers. The oil compartments in açaí fruit contain polyphenols such as procyanidin oligomers and vanillic acid, syringic acid, p-hydroxybenzoic acid, protocatechuic acid, and ferulic acid, which were shown to degrade substantially during storage or exposure to heat. Although these compounds are under study for potential health effects, there remains no substantial evidence that açaí polyphenols have any effect in humans. Açaí oil is green in color, has a bland aroma, and is high in oleic and palmitic fatty acids.
Insulin therapy can be injection under the skin multiple times a day, or can be delivered continuously as a basal amount with boluses for high blood sugar or before meals using an insulin pump. A diabetic diet, exercise, and lifestyle modifications are considered cornerstones of management. If left untreated, type 1 diabetes results in death. Type 1 diabetes can cause many complications if blood sugar control is not very well controlled. Complications of relatively rapid onset include diabetic ketoacidosis and nonketotic hyperosmolar coma. Long-term complications include heart disease, stroke, kidney failure (Diabetic Nephropathy), foot ulcers, and damage to the eyes (diabetic retinopathy). As insulin lowers blood sugar levels, complications may arise from low blood sugar if more insulin is taken than necessary. Type 1 diabetes makes up an estimated 5–10% of all diabetes cases. The number of people affected globally is unknown, although it is estimated that about 80,000 children develop the disease each year. Within the United States the number of people affected is estimated to be one to three million. Rates of disease vary widely, with approximately one new case per 100,000 per year in East Asia and Latin America and around 30 new cases per 100,000 per year in Scandinavia and Kuwait. It typically begins in children and young adults but can begin at any age.
N2 + 16 MgATP + 8 e− → 2 NH3 + 16 MgADP +16 Pi + H2 where Pi stands for inorganic phosphate. The precise structure of the active site has been difficult to determine. It appears to contain a MoFe7S8 cluster that is able to bind the dinitrogen molecule and, presumably, enable the reduction process to begin. Some species of bacteria and archaea have also been shown to have Vanadium nitrogenases, which contain a VFe3S4 cluster and allows for an alternative pathway of nitrogen fixation in Molybdenum-deficient conditions. The electrons are transported by the associated "P" cluster, which contains two cubical Fe4S4 clusters joined by sulfur bridges.
South Africa and Portugal, Rhodesia's largest trading partners, also refused to extend diplomatic recognition, and did not open embassies in the Rhodesian capital, Salisbury, preferring to conduct diplomatic activities through "accredited representatives". This allowed the South African and Portuguese governments to maintain they were continuing to respect British sovereignty while also accepting the practical authority of the Smith administration. Initially, the Rhodesian state retained its pledged loyalty to Queen Elizabeth II, recognising her as Queen of Rhodesia. When Smith and Deputy Prime Minister Clifford Dupont visited Sir Humphrey Gibbs, the Governor of Southern Rhodesia, to formally notify him of the UDI, Gibbs condemned it as an act of treason. After Smith formally announced the UDI on the radio, Governor Gibbs used his reserve power to dismiss Smith and his entire cabinet from office, on orders from the Colonial Office in Whitehall. However, Gibbs was unable to take any concrete actions to bring about a return to lawful colonial government. Rhodesian ministers simply ignored his notices, contending that UDI had made his office obsolete. Even so, Gibbs continued to occupy his official residence, Government House, in Salisbury until 1970, when he finally left Rhodesia, following the declaration of a republic. He had effectively been superseded before then; the Smith government stated that if the Queen did not appoint a Governor-General, it would name Dupont as "Officer Administering the Government".
== Figurative use == The term poison is also used in a figurative sense. The slang sense of alcoholic drink is first attested 1805, American English (e.g., a bartender might ask a customer "what's your poison?" or "Pick your poison"). Figurative use of the term dates from the late 15th century. Figuratively referring to persons as poison dates from 1910. The figurative term poison pen letter became well known in 1913 by a notorious criminal case in Pennsylvania, U.S.; the phrase dates to 1898. Despite the plants of the Toxicodendron family having the names poison ivy and poison oak, the oil urushiol they produce is not a true poison and is actually an allergen, which 15% of people are resistant to.
Sources: en.wikipedia.org
Moscow contains 96 parks and 18 gardens, including four botanical gardens. The city contains 450 square kilometers (170 sq mi) of green space in addition to 100 square kilometers (39 sq mi) of forests. Moscow is green in comparison with other cities of comparable size in Western Europe and North America; this stems partly from a history of green "yards" with trees and grass between residential buildings. Moscow contains on average 27 square meters (290 sq ft) of parks per person, compared with 6 square meters in Paris, 7.5 in London and 8.6 in New York.
Relatively strong reducing acids can have antinutrient effects by binding to dietary minerals such as iron and zinc in the gastrointestinal tract and preventing them from being absorbed. Examples are oxalic acid, tannins and phytic acid, which are high in plant-based diets. Calcium and iron deficiencies are not uncommon in diets in developing countries where less meat is eaten and there is high consumption of phytic acid from beans and unleavened whole grain bread. However, germination, soaking, or microbial fermentation are all household strategies that reduce the phytate and polyphenol content of unrefined cereal. Increases in Fe, Zn and Ca absorption have been reported in adults fed dephytinized cereals compared with cereals containing their native phytate.
==== MeSH E05.300.120 – administration, topical ==== MeSH E05.300.120.040 – administration, buccal MeSH E05.300.120.060 – administration, cutaneous MeSH E05.300.120.080 – administration, intranasal MeSH E05.300.120.500 – administration, intravaginal MeSH E05.300.120.505 – administration, intravesical MeSH E05.300.120.610 – administration, rectal
The drug's primary indication was the treatment of penicillin-resistant Staphylococcus aureus. The drug was given to a patient who had developed a severe infection on his foot after surgery which had been unresponsive to multiple antibiotics. The surgical staff had recommended amputation or the use of the new antibiotic. His answer was, "Anything that might save my foot". Due to the spread of the bacteria, a high dosage of the antibiotic 05865 was recommended, 100 mg every eight hours, over five days. After the first day, the heat was decreasing, his white cell count was dropping, and the exudate of his wound was less. During the next seven days, the staphylococci disappeared from the wound, and his foot was free from any sign of infection. Two months later, he left the hospital with an intact foot. The drug was fast-tracked for approval by the Food and Drug Administration due to the clinical need for effective anti-staphylococcal agents and an observed lack of resistance development in serial passage in culture media with the drug. The origins of the generic name vancomycin differ; some sources state the name was is linked to the term "vanquish", with others stating it came from the Latin word "vanesco", which means to vanish or disappear. In 1958, Eli Lilly began marketing vancomycin hydrochloride under the trade name Vancocin. Vancomycin never became the first-line treatment for S. aureus for several reasons:
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.